Applied UV Installs Patented LumiCide Surface Disinfection Solution into NYC's Mt. Sinai Medical Center Morningside

Applied UV Installs Patented LumiCide Surface Disinfection Solution into NYC's Mt. Sinai Medical Center Morningside

One of The World's Prestigious Hospitals

Applied UV, Inc. (NasdaqCM: AUVI ) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announces that its wholly owned subsidiary SteriLumen has just installed its patented LumiCide Surface and Drain UVC Disinfecting Systems initially, in 17 patient rooms within the world renowned Mt. Sinai Medical Center Morningside. Mount Sinai Morningside , formerly known as Mount Sinai St. Luke's, is a teaching hospital located in the Morningside Heights neighborhood of Manhattan in New York City.

Mt. Sinai plans to publish the results in an Academic Paper later this summer which would further validate the previously obtained independent results conducted by ResInnova Laboratories. This validation could facilitate the adoption of our LumiCide Surface and Drain disinfection solutions throughout healthcare facilities globally.

Mount Sinai Morningside is affiliated with the Icahn School of Medicine at Mount Sinai and the Mount Sinai Health System, a nonprofit hospital system formed by the merger of Continuum Health Partners and the Mount Sinai Medical Center in September 2013. It provides general medical and surgical facilities, ambulatory care, and a Level 2 Trauma Center, verified by the American College of Surgeons. It operates 21 clinics and as of 2020, is nationally ranked by U.S. News & World Report .

John F. Andrews Applied UV's CEO and Director stated, "We welcome Mt. Sinai Medical Center to the Applied UV Family. The addition of this premier, globally recognized, and respected teaching institution to our growing list of leading hospitals who place their trust in our patented disinfection products (both air and surface) is further testament to the proven effectiveness but also, too the growing interest of globally recognized brands and companies who use our family of solutions to protect their facilities, employees, and products from harmful airborne and surface related pathogens. We look forward to a long and successful relationship with the Mt. Sinai team."

The LumiCide Disinfection System product line has the following attributes:

  • Focus on the sink area and drain . Focuses on pathogens that accumulate on the sink area, including handles, faucets and backsplash and in the drain.
  • UVC LED Pathogen Destruction . Destroys 4 logs (99.99%) some of the most dangerous pathogens like COVID 19, MERSA C'diff, in the bathroom vanity/sink area with at least two hours of continuous use.
  • Automatic operation . Built-in programmable controller that ensures operation for the full required daily time and is not dependent on manual operation.
  • Continuous operation . Works in cycles of two hour on and four hours off, except for the disinfecting drain which is on 15 minutes every hour. The timing protocol is managed by a programmable controller and a motion detector enclosed within each device and works while the room is still occupied and while the bathroom is not in use, therefore, continuously disinfecting an area of ongoing high contamination.
  • Safety . Built-in motion detector and sensor automatically shuts off the UVC light when anyone enters the room eliminating any concern over UV safety. Once there is no movement in the room for 10 minutes the UVC light comes back on to restart and continue its cycle.
  • Removable UVC LED panel . The UVC LEDs are installed via a removable panel, leading to ease of replacement or upgrade.
  • Ease of Installation . The unit is easy to install and uses standard electrical wiring.
  • IOT connectivity . IOT connectivity uses Wi-Fi and RF technology that will enable continuous transmission of use and functionality data over the Internet for collection and analysis.

Applied UV's internal research and research provided by the CDC estimates that each year about 1 in 25 U.S. hospital patients (approximately 1.4M Americans) are diagnosed with at least one infection related to hospital care alone and additional infections occur in other healthcare settings. Approximately 900,000 Americans die each year due to complications associated with Hospital Acquired Infections. Many HAI's are caused by the most urgent and serious antibiotic -resistant (AR) bacteria and my lead to sepsis of death. According to NIH, Healthcare-associated infections are known to increase the length of stay, health care costs, and mortality. Each year the top 5 healthcare-associated infections result in about $9.8 billion costs.

About Applied UV

Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. ("SteriLumen") and Munn Works, LLC ("Munn Works"). SteriLumen's connected platform for Data Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company's Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices' proximity. The Company's patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen intensive location. SteriLumen's Airocide® air purification devices are research backed, clinically proven, and developed for NASA with assistance from the University of Wisconsin. Airocide® is listed as an FDA Class II Medical device, utilizes a proprietary photocatalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine making facilities, commercial real estate, schools, dental offices, post-harvest, grocery, cannabis facilities and homes. For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: https://www.applieduvinc.com

Forward-Looking Statements

The information contained herein may contain "forward‐looking statements." Forward‐looking statements reflect the current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward‐looking statements are based on the Company's current expectations and assumptions regarding its business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward‐looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward‐looking statements. Factors or events that could cause the Company's actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward‐looking statements to conform these statements to actual results.

Applied UV Inc.
John F. Andrews
Applied UV CEO & Director
john.andrews@applieduvinc.com

Brett Maas, Managing Principal
Hayden IR
brett@haydenir.com
(646) 536-7331

News Provided by Business Wire via QuoteMedia

AUVI:NSD
The Conversation (0)
Nextech3D.ai Receives Notice From USPTO To Be Granted Pivotal AI Patent for Generating 3D Models from 2D images

Nextech3D.ai Receives Notice From USPTO To Be Granted Pivotal AI Patent for Generating 3D Models from 2D images

Nextech3D.ai (OTCQX:NEXCF)(CSE:NTAR)(FSE:EP2), a Generative AI-Powered 3D model supplier for Amazon, P&G, Kohls and other major e-commerce retailers is excited to announce that U.S. Patent and Trademark Office (USPTO) has informed of their decision to issue a patent for its technology to generate three-dimensional (3D) models from two-dimensional (2D) images. This is another patent which the Company believes is pivotal to Nextech3D.ai's artificial intelligence technology as it builds a moat around its 3D model making for ecommerce business with industry expertise and intellectual property; which includes its GPT AI powered 3D model generation. This patent approval reinforces and validates Nextech3D.ai's commitment to increasing shareholder value by investing in 3D-AI GPT patents and solutions while simultaneously generating millions in annual 3D modeling revenue

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
E-Power Resources Inc. Announces Approval of Deal with Volt Carbon Technologies

E-Power Resources Inc. Announces Approval of Deal with Volt Carbon Technologies

E-Power Resources Inc (CSE: EPR) ("E-Power" or the "Company") is pleased to announce it has issued the first tranche of 1,600,000 shares to Volt Carbon Technologies Inc ("Volt Carbon") as part of the option agreement announced on February 5, 2024.

The Company issued 1,600,000 shares to Volt Carbon on March 21, 2024. The shares are subject to a 4-month hold period. The Company will issue Volt Carbon another 2,500,000 shares when $340,000 is spent on exploration of the Tetepisca Property and a further 2,500,000 shares when the second $340,000 is spent on exploration of the Tetepisca Property. Volt Carbon has agreed to spend the full $680,000 during the 2024 calendar year. Spending the entire $680,000 on exploration of the Tetepisca Property, before December 31, 2024, will give Volt Carbon the right to acquire a 5% interest in the Tetepisca Property, on or before December 31, 2025, for a $1,500,000 cash payment.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
ARway.ai Announces Major 300,000 SQ FT or 30,000 M. Retail Store Pilot of its AR Navigation Platform

ARway.ai Announces Major 300,000 SQ FT or 30,000 M. Retail Store Pilot of its AR Navigation Platform

ARway.ai ("ARway" or the "Company") (CSE:ARWY)(OTCQB:ARWYF)(FSE:E65) is an AI powered Augmented Reality Experience platform with a disruptive no-code, no beacon spatial computing solution enabled by visual marker tracking with centimeter precision is pleased to announce its new partnership with Megatek Albania's leading home improvement and do-it-yourself (DIY) retailer. This groundbreaking collaboration is set to bring an unprecedented retail experience to the Albanian market, beginning with a pilot program at Megatek's expansive flagship store that spans more than 323,000 square feet

The successful implementation of ARway's technology in Megatek's flagship store will pave the way for future deployments across more locations and similar stores, signaling a significant growth and revenue opportunity for both companies.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
NEO Battery Materials Announces Change of Auditor to MNP LLP

NEO Battery Materials Announces Change of Auditor to MNP LLP

NEO Battery Materials Ltd. (" NEO " or the " C o mpan y ") ( T S X V : NBM ) ( OTC: NBMFF ), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce that it has changed its auditors from DeVisser Gray LLP (" Former Auditor ") to MNP LLP (" Successor Auditor "), effective March 19, 2024.

NEO Battery's board of directors accepted the resignation of DeVisser Gray LLP and appointed MNP LLP as the new auditor of the Company, effective March 19, 2024, until the Company's next annual general meeting of shareholders.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

NANALYSIS ANNOUNCES CLOSING OF PREVIOUSLY ANNOUNCED BEST EFFORTS PROSPECTUS EXEMPT OFFERING PURSUANT TO THE LISTED ISSUER EXEMPTION AND CONCURRENT PRIVATE PLACEMENT

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES ./

Nanalysis Scientific Corp. (TSXV: NSCI) (the " Company " or " Nanalysis ") is pleased to announce that it has closed its prospectus exempt offering of units (the " Offering ") and concurrent brokered "best efforts" prospectus exempt offering of units (the " Concurrent Offering" ), as announced on March 6, 2024 . A total of 11,111,110 units (the " Units ") were issued at a price of $0.45 per Unit for gross proceeds of $4,999,999.50 . A total of 8,888,888 Units were issued pursuant to the Offering and 2,222,222 Units were issued pursuant to the Concurrent Offering.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
ARway.ai Announces EWROS as New Partner in Turkey for its Augmented Reality Navigation Experience Platform

ARway.ai Announces EWROS as New Partner in Turkey for its Augmented Reality Navigation Experience Platform

ARway.ai ("ARway" or the "Company") (CSE:ARWY)(OTCQB:ARWYF)(FSE:E65) is an AI powered Augmented Reality Experience platform with a disruptive no-code, no beacon spatial computing solution enabled by visual marker tracking with centimeter precision is pleased to announce a paid partner deal with EWROS, a leading developer of automation systems software based out of Turkey. This new partner is another step in ARway.ai's expansion, aligning with EWROS's recognized position in the region as a premier automation solutions provider

EWROS becomes an integral part of the ARway ecosystem, licensing ARway's innovative platform for large-scale projects within the region. This partnership allows EWROS to leverage ARway's cutting-edge AR technology in conjunction with their existing IoT deployments, thereby offering a comprehensive tech stack to their clientele.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×